1	The impact of fatty acids biosynthesis on the risk of cardiovascular diseases in
2	Europeans and East Asians:
3	A Mendelian randomization study
4	
5	Maria Carolina Borges, ^{1,2,*}
6	Phillip Haycock, ^{1,2}
7	Jie Zheng, ^{1,2}
8	Gibran Hemani, ^{1,2}
9	Laurence J Howe, ^{1,2}
10	A Floriaan Schmidt, ^{3,4}
11	James R Staley, ^{1,2}
12	R Thomas Lumbers, ^{5,6,7}
13	Albert Henry, ^{3,5,7}
14	Rozenn N Lemaitre, ⁸
15	Tom R Gaunt, ^{1,2}
16	Michael V Holmes, ^{9,10}
17	George Davey Smith, ^{1,2}
18	Aroon D Hingorani, ^{3,6,7,#}
19	Deborah A Lawlor, ^{1,2,11,#}
20	[#] These authors contributed equally to this work
21	
22	1 MRC Integrative Epidemiology Unit, University of Bristol, Bristol, BS8 2BN, UK.

- 23 2 Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, BS8
- 24 2PN, UK.

2

- 25 3 Institute of Cardiovascular Science, Faculty of Population Health Sciences, University
- 26 College London, London, WC1E 6DD, UK.
- 27 4 Department of Cardiology, Division Heart and Lungs, UMC Utrecht, Utrecht, 3584 CX,
- 28 Netherlands.
- 29 5 Institute of Health Informatics, University College London, London, NW1 2DA, UK.
- 30 6 Health Data Research UK London, University College London, NW1 2DA, UK.
- 31 7 UCL British Heart Foundation Research Accelerator, London, NW1 2DA, UK.
- 32 8 Cardiovascular Health Research Unit, Department of Medicine, University of Washington,
- 33 Seattle, WA, WA 98101, USA.
- 34 9 Medical Research Council Population Health Research Unit, University of Oxford, Oxford,
- 35 OX3 7LF, UK.
- 36 10 Clinical Trial Service and Epidemiological Studies Unit, Nuffield Department of
- 37 Population Health, University of Oxford, Oxford, OX3 7LF, UK.
- 38 11 NIHR Bristol Biomedical Research Centre, Bristol, BS8 2BN, UK.
- 39
- 40
- 41 **Correspondence email:** <u>m.c.borges@bristol.ac.uk</u>
- 42 **Twitter handle:** @MCarol_Borges
- 43 Short title: Mendelian randomization, fatty acids and cardiovascular diseases

45 ABSTRACT

46 Despite early interest, the evidence linking fatty acids to cardiovascular diseases remains 47 controversial. We used Mendelian randomization to explore the involvement of 48 polyunsaturated (PUFA) and monounsaturated (MUFA) fatty acids biosynthesis in the 49 aetiology of several cardiovascular disease endpoints in up to 1,153,768 European and 50 212,453 East Asian ancestry individuals. As instruments, we selected single nucleotide 51 polymorphisms (SNP) mapping to genes with well-known roles in PUFA (i.e. FADS1/2 and 52 ELOVL2) and MUFA (i.e. SCD) biosynthesis. Our findings suggest that higher PUFA 53 biosynthesis rate (proxied by rs174576 near FADS1/2) is related to higher odds of multiple 54 cardiovascular diseases, particularly ischemic stroke, peripheral artery disease and venous 55 thromboembolism, whereas higher MUFA biosynthesis rate (proxied by rs603424 near SCD) 56 is related to lower odds of coronary artery disease among Europeans. Results were unclear 57 for East Asians as most effect estimates were imprecise. By triangulating multiple approaches 58 (i.e. uni-/multi-variable Mendelian randomization, a phenome-wide scan, genetic 59 colocalization and within-sibling analyses), our results are compatible with higher low-60 density lipoprotein (LDL)-cholesterol (and possibly glucose) being a downstream effect of 61 higher PUFA biosynthesis rate. Our findings indicate that genetically-determined PUFA and 62 MUFA biosynthesis are involved in the aetiology of cardiovascular diseases and suggest 63 LDL-cholesterol as a potential mediating trait between PUFA biosynthesis and 64 cardiovascular diseases risk.

65 Key

Key words: fatty acids, cardiovascular diseases, Mendelian randomization

66 **INTRODUCTION**

67

68 Fatty acids constitute the main components of dietary fats and are required in human 69 nutrition as a source of energy and for metabolic and structural activities (1). They are 70 capable of influencing a wide range of cell signalling pathways and have been implicated in 71 the regulation of several processes involved in the aetiology of cardiovascular diseases, 72 including lipid metabolism (2-4), glucose homeostasis (5, 6), blood pressure (7-9), 73 inflammatory response (10-12), and endothelial function (9, 13). Fatty acids are commonly 74 subdivided into broad classes according to the degree of unsaturation (i.e., number of carbon-75 carbon double bonds) into saturated (SFA), monounsaturated (MUFA) and polyunsaturated 76 (PUFA) fatty acids, the latter being classified as omega-3 or omega-6 PUFA depending on 77 the position of the first double bond from the terminal methyl group.

78 Some fatty acids can be synthesized endogenously by fatty acid synthase or taken up 79 by diet and further elongated and desaturated into longer chain fatty acids by fatty acid 80 elongases and desaturases, respectively (14). Genome-wide association studies (GWAS) have 81 reported that circulating fatty acids are strongly influenced by genetic variants near genes 82 coding fatty acid elongases and desaturases: fatty acid desaturase 1 (FADS1 -83 ENSG00000149485), fatty acid desaturase 2 (FADS2 - ENSG00000134824), elongase 2 84 (ELOVL2 - ENSG00000197977), and stearoyl-CoA desaturase (SCD - ENSG00000099194) 85 (15-21). The chemical reactions and pathways catalysed by the enzymes encoded by FADS1, 86 FADS2, ELOVL2, and SCD are summarised in Figure 1.

87 Mendelian randomization uses genetic variants associated with putative risk factors as 88 instruments to assess their involvement in disease aetiology (22-24). The use of human 89 genetics to explore the effect of modifiable risk factors on cardiometabolic diseases, such as

5

90 in Mendelian randomization, has proven valuable to (de)prioritise targets for intervention and
91 to assess potential target-mediated adverse effects reducing late-stage failures in RCTs due to
92 lack of efficacy or from target-mediated adverse reactions (25).

93 Genetic variants affecting the expression or activity of genes encoding for fatty acid 94 elongases and desaturases (e.g. FADS1/2, ELOVL2, and SCD) can be used as causal anchors 95 in Mendelian randomization studies investigating the involvement of fatty acids in the 96 development of cardiovascular diseases. Most previous Mendelian randomization studies 97 investigating the role of fatty acids on the risk of cardiovascular diseases have relied solely or 98 heavily on genetic variants within the FADS1/2 locus involved in PUFA synthesis by 99 encoding the enzymes delta-5 desaturase (D5D) and delta-6 desaturase (D6D), respectively. 100 Overall, these studies have reported that shorter (e.g. α -linolenic acid (ALA) and linoleic acid 101 (LA)) and longer (e.g. arachidonic acid (AA)) chain PUFA are associated with lower and 102 higher risk of cardiovascular diseases, respectively (26-32).

103 These studies potentially strengthen the evidence on the involvement of fatty acids in 104 the development of cardiovascular diseases given the well-established link of D5D/D6D with 105 PUFA biosynthesis. However, such studies suffer from a critical limitation given FADS1/2 106 variants are not reliable instruments for individual fatty acids. First, FADS1/2 variants will 107 affect multiple fatty acids on the same pathway and, in some cases, on different pathways 108 with reactions catalysed by D5D/D6D (Figure 1). Second, these studies have not extensively 109 explored whether the association of FADS1/2 variants with cardiovascular diseases risk could 110 be explained by biological pathways independent of fatty acids (e.g. if variants 111 simultaneously influence the expression of other genes in the region that affect cardiovascular 112 diseases) or due to confounding by population stratification or other familial mechanisms 113 (e.g., indirect genetic effects).

6

The aim of this study was to use Mendelian randomization to explore the effect of fatty acids biosynthesis on a wide range of cardiovascular disease end-points in up to 1,153,768 European and 212,453 East Asian ancestry individuals. We extend work in previous studies by using genetic variants regulating multiple rate-limiting enzymes in fatty acids biosynthesis (i.e. D5D/D6D, ELOVL2 and SCD), comparing findings between Europeans and East Asians and extensively exploring the key scenarios that could lead to spurious findings in this and previous Mendelian randomization studies.

121 MATERIAL AND METHODS

122

123 Study design

We used two-sample Mendelian randomization to probe the lifelong effect of fatty acids biosynthesis on the risk of multiple cardiovascular diseases in Europeans and East Asian individuals. As instruments, we selected genetic variants mapping to genes with a wellknown role in fatty acids biosynthesis (i.e. *FADS1/2*, *ELOVL2*, and *SCD*). We used two approaches to circumvent limitations in previous studies.

First, we used genetic variants to instrument for enzyme activity in a given fatty acids biosynthesis pathway (rather than for individual fatty acids) by deriving the ratio between fatty acids that are the product and the substrate of a reaction catalysed by the corresponding enzyme. This allows harnessing the advantages of cis-acting variants in the vicinity of genes coding for key enzymes in fatty acids biosynthesis pathways and can provide more credible evidence on the likely therapeutic benefit of targeting such protein in preventing cardiovascular diseases(33).

136 Second, we used a range of methods to assess the plausibility of the four key 137 scenarios that could invalidate inferences from this and previous studies: (i) horizontal 138 pleiotropy, where the genetic variant influences the outcome via a different biological 139 pathway; (ii) confounding by *linkage disequilibrium* (LD), where the selected genetic variant 140 is in LD with another genetic variant influencing the outcome independently; (iii) 141 confounding by population stratification, assortative mating or indirect genetic effects, which 142 could create a spurious association between genetic variant and outcome, and (iv) selection 143 bias, where the genetic variant (or, more likely, its downstream traits) and the outcome affect 144 selection into the sample resulting in a spurious association (Figure 2).

8

145

146 Data sources

147 The study included data from multiple consortia of genetic association studies (34-38)148 and biobanks (39-45).

149

150 Genetic associations with cardiovascular disease outcomes

151 The outcomes of interest were (prevalent/incident) coronary artery disease, ischemic 152 stroke, haemorrhagic stroke, heart failure, atrial fibrillation, peripheral arterial disease, aortic 153 aneurysm, venous thromboembolism, and aortic valve stenosis.

154 Summary data for the association between genetic variants and these cardiovascular 155 disease endpoints was obtained from UK Biobank, FinnGen, BioBank Japan and several 156 large-scale genetic consortia of cardiovascular disease outcomes. If genetic association data 157 on a cardiovascular endpoint were available from two or more independent datasets of 158 individuals from the same genetic ancestry (i.e. UK Biobank and FinnGen), genetic 159 association estimates were pooled across data sources using fixed-effect meta-analysis with 160 inverse variance weights. Characteristics of studies and criteria for case definition are 161 detailed in **Supplementary table 1** and **Supplementary methods**.

162 For individuals of European ancestry only/predominantly (i.e. UK Biobank, 163 FinnGen and large-scale genetic consortia), data were available on all outcomes of interest: 164 coronary artery disease (N cases/controls = 123,668/702,156), ischemic stroke (N 165 cases/controls \equiv 53,395/1,030,253), haemorrhagic stroke (N cases/controls 166 4,558/627,188), heart failure (N cases/controls = 64,696/1,089,072), atrial fibrillation (N cases/controls = 77,945/1,067,430), peripheral arterial disease (N cases/controls = 167 168 9,836/627,950), aortic aneurysm (N cases/controls 9,735/730,073), = venous

9

169 thromboembolism (N cases/controls = 25,284/616,235), and aortic valve stenosis (N cases/controls = 2,844/461,776).

For individuals of East Asian ancestry (i.e. BioBank Japan), cardiovascular outcomes data were available for coronary artery disease (N cases/controls = 29,319/183,134), ischemic stroke (N cases/controls = 17,671/192,383), haemorrhagic stroke (N cases/controls = 2,820/192,383), heart failure (N cases/controls = 9,413/203,040), atrial fibrillation (N cases/controls = 8,180/28,612), and peripheral arterial disease (N cases/controls = 3,593/208,860).

177

178 Genetic associations with circulating fatty acid concentration

For European ancestry individuals, we used genetic association data on circulating fatty acids from *The Cohorts for Heart and Aging Research in Genomic Epidemiology* (CHARGE) consortium, which has high resolution profiling of circulating fatty acids (N = 26 fatty acids measures) measured in 8,631-8,866 individuals (15-17). We also used data from two other genetic association meta-analyses on circulating fatty acids (18, 19) for assessing replication as detailed in 'Data analysis' under 'Assessing the impact of genetic instruments on the fatty acids pool'.

For East Asian ancestry individuals, we used genetic association data on fatty acids from the Singapore Chinese Health Study (SCHS) for circulating PUFA (N = 1,361) (21) and from a metanalysis of the Nutrition and Health of Aging Population in China (NHAPC) and the Chinese ancestry individuals of the Multi-Ethnic Study of Atherosclerosis (MESA) for RBC or circulating SFA and MUFA (N = 3,521) (46, 47).

- 191 Characteristics of these studies are detailed in **Supplementary table 2**.
- 192

193 Data analysis

194 Selection of genetic instruments indexing fatty acids biosynthesis

195 We selected genetic variants mapping to genes that have well-characterised roles in 196 fatty acids biosynthesis and have been previously reported by GWAS to influence circulating 197 fatty acids (Figure 1). In Europeans, three genomic regions were eligible, harbouring 198 FADS1/2, ELOVL2 and SCD genes, whereas, in East Asians, only the FADS1/2 locus was 199 strongly associated with circulating fatty acids, which may be related to the modest sample 200 size available for East Asians (N = 1,361-3,521). FADS1/2 were considered as one single 201 genomic region since these genes are in close proximity to each other (i.e. 0.8 kb) on the long 202 arm of human chromosome 11.

203 Genetic variants regulating the expression/activity of FADS1/2, ELOVL2 and SCD 204 will affect multiple fatty acids on the same pathway and, in some cases, on different 205 pathways with reactions catalysed by the same enzymes (Figure 1). As a result, selecting 206 genetic variants for individual fatty acids can be highly redundant. Instead, we selected the genetic variant (\pm 500 kB of the target gene) most strongly related (p-value < 5 x 10⁻⁸) to a 207 208 proxy of the enzyme activity (i.e. the ratio between fatty acids that are the product and the 209 substrate of a reaction catalysed by a particular enzyme) within each genomic locus (details 210 in **Supplementary methods**). As an example, a higher ratio of AA to dihomo- γ -linoleic acid 211 (DGLA) would indicate more active conversion due to higher expression/activity of D5D, the 212 enzyme encoded by FADS1.

For European ancestry individuals, we derived genetic association data for proxies of enzyme activity by applying the GWIS ("Genome-wide Inferred Study") method to genetic association data for circulating fatty acids from the CHARGE consortium (15-17) for the ratios of AA to DGLA (proxy of D5D activity), γ-linolenic acid (GLA) to LA (proxy of D6D

activity), docosahexaenoic acid (DHA) to docosapentaenoic acid (DPA n-3) (proxy of
ELOVL2 activity), and palmitoleic acid (POA) to palmitic acid (PA) (proxy of SCD activity),
as detailed in **Supplementary methods**. Briefly, GWIS approximates GWAS summary
statistics for a new variable as a function of multiple phenotypes for which GWAS summary
statistics, phenotypic means, and covariances are available (48).

For East Asian ancestry individuals, the original GWAS investigators derived genetic association data for the proxies of enzyme activity from individual level data on circulating fatty acids (21), as follows: AA to DGLA (proxy of D5D activity) and DGLA to LA (proxy of D6D activity).

If the selected genetic variant was a palindromic SNP, it was replaced by a nonpalindromic proxy variant in strong LD to avoid data harmonisation problems in subsequent analyses. All SNP-trait associations were harmonised so that the allele associated with increasing enzyme activity was the effect allele, indicating more active conversion. We approximated the R^2 , a measure of the variance in exposure explained by the genetic variant, and the F-statistics, a measure of instrument strength (49), as detailed in **Supplementary methods**.

233

234 Assessing the impact of genetic instruments on the fatty acids pool

We assessed the impact of the selected genetic instruments on the circulating fatty acids pool in the discovery samples (i.e. CHARGE in Europeans and SCHS in East Asians) for internal validation. Among European ancestry individuals, we could test for replication in two independent datasets (external validation) (18, 19).

239

240 Mendelian randomization analysis

12

241 For each cardiovascular outcome, we used the Wald ratio method to estimate the odds 242 ratio of disease per standard unit increase in enzyme activity by dividing estimates for the 243 genetic association with cardiovascular outcome by estimates for the genetic association with 244 enzyme activity as detailed in the **Supplementary methods**. We used a Bonferroni 245 correction to account for the number of outcomes available in Europeans (p-value = 0.05/9246 outcomes = 0.006) and East Asians (p-value = 0.05/6 outcomes = 0.008). We use these p-247 value thresholds simply as a heuristic for highlighting associations worthy of follow-up. 248 Mendelian randomization analyses were performed using R software version 3.6.2 (R 249 Foundation for Statistical Computing) including the TwoSampleMR R package (50).

250

251 *Exploring bias in Mendelian randomization analyses*

We explored the validity of our Mendelian randomization findings by assessing whether results are likely to be spurious due to horizontal pleiotropy, population stratification, assortative mating, indirect genetic effects, and selection bias as follows.

255

256 Horizontal pleiotropy

Horizontal pleiotropy is one of the main threats to the validity of Mendelian randomization studies since it is a widespread biological phenomenon (51) and it cannot be empirically verified. We combined two approaches to explore the plausibility that our results are explained by horizontal pleiotropy: phenome scan and multivariable Mendelian randomization to adjust for the potential effect of other genes expressed in the candidate genomic regions.

263

264 Phenome scan

13

We explored the potential mechanisms that might link the selected genetic variants to cardiovascular diseases by testing their association with well-established cardiovascular risk factors (hypothesis-driven approach) and across the phenome (hypothesis-free approach) (52).

In the hypothesis-driven approach, we tested for the association between the selected genetic variants and eight well-established risk factors for cardiovascular diseases [i.e. lowdensity lipoprotein (LDL)-cholesterol, triglycerides, systolic, diastolic blood pressure, fasting glucose, type 2 diabetes, smoking, and body mass index] using Bonferroni correction to account for multiple testing (p-value = 0.05/8 risk factors). Genetic association data for these risk factors were extracted from UK Biobank (only/predominantly) and BioBank Japan using the IEU OpenGWAS project database (53).

In the hypothesis-free (phenome-wide) approach, we used an automated phenomewide scan tool from the IEU OpenGWAS project database (53) to test the association of the selected genetic variants with 32,534-34,465 (non-unique) traits for European ancestry individuals and 110 traits for Japanese individuals from BioBank Japan. We used a Bonferroni correction to account for multiple testing considering the maximum number of traits included in the phenome-wide scan in Europeans (p-value = $0.05/34,465 = 1.5 \times 10^{-6}$) and East Asians (p-value = $0.05/110 = 4.5 \times 10^{-4}$).

283

284 Gene expression and tissue-specific analyses

We explored the influence of higher expression of the target genes (i.e. *FADS1/2*, *ELOVL2* and *SCD*), and their tissue specificity, on cardiovascular disease risk and risk factors by integrating expression quantitative trait loci (eQTL) data from Genotype-Tissue Expression (GTEx) version 8 with genetic association data for cardiovascular traits, as

14

289 detailed in **Supplementary methods**. First, we performed a cross-tissue assessment of the 290 association of the selected genetic variants with transcription of cis-genes, defined as genes 291 for which the transcription start site was 1 Mb away from the genetic variant. Second, we 292 used multivariable Mendelian randomization to jointly model the expression of a target gene 293 (i.e. FADS1/2, ELOVL2, and SCD) and a co-expressed cis-gene on cardiovascular outcomes 294 across tissues using the MVMR R package (54). This analysis allowed us to estimate the 295 direct contribution of changes in the expression of each target gene where the selected genetic 296 variant was related to co-expression of a non-target cis-gene.

297

298 Confounding by linkage disequilibrium

299 Linkage disequilibrium (LD) could lead to spurious results in Mendelian 300 randomization analysis if, by chance, the selected genetic variant influencing fatty acids 301 biosynthesis is correlated (i.e. in LD) with another genetic variant influencing the risk of 302 cardiovascular diseases independently. We used coloc (55), a method for pairwise genetic 303 colocalization analysis, to test whether the same genetic variant influences fatty acids 304 biosynthesis and cardiovascular diseases risk. A posterior probability of association (PPA) \geq 305 70% for association with both traits due to a single causal variant was considered as strong 306 evidence for a shared genetic variant.

307 *Coloc* assumes a single causal variant in the genomic region, and, as a result, the 308 presence of multiple conditionally independent SNPs within a region can affect the 309 performance of the method. Therefore, where *Coloc* provided evidence of a shared genetic 310 signal, we also performed approximate conditional analyses using GCTA(56, 57) (adjusting 311 for the top SNP in each genomic region) and re-ran *Coloc* using the adjusted association 312 estimates as a sensitivity analyses.

15

Colocalization analyses were restricted to European datasets as the method assumes that samples are drawn from independent populations of similar genetic background (i.e. allele frequencies and LD pattern are identical), which was not the case for East Asians in our analyses since fatty acids and cardiovascular disease data were derived from Singaporean Chinese and Japanese individuals, respectively.

318

319 <u>Population stratification, assortative mating and indirect genetic effects</u>

320 Mendelian randomization studies generally assume that genetic association estimates 321 from GWAS reflect the direct effect of a genetic variant on a phenotype, i.e., the downstream 322 effect of inheriting an allele. However, there is growing evidence that GWAS of unrelated 323 individuals may also capture non-direct sources of association relating to population 324 stratification, assortative mating and indirect genetic effects of parents(58). Within-family 325 GWAS/Mendelian randomization designs, such as parent-offspring trio or within-sibship 326 models, control for variation in parental genotypes, and so are not affected by these potential 327 biases (59-61).

328 There is evidence that the FADS1/2 locus was under important selection pressure in 329 different populations and at different times, possibly as a response to dietary changes and the 330 need for adequate supply of essential long-chain PUFA from precursors (62). Despite 331 attempts to control for population stratification in genetic association data (e.g. by adjusting 332 for genomic principal components), there could still be residual population structure as has 333 recently been shown in UK Biobank (63). In addition, there is a possibility that indirect 334 genetic effects of parents bias studies among unrelated individuals given the literature 335 suggesting that maternal genotype for FADS1/2 variants might indirectly influence offspring 336 outcomes via intrauterine effects and/or breastfeeding (64).

16

337 We used two approaches to explore this. First, we tested the association between the 338 selected genetic variants with two negative control outcomes, skin colour and ease of skin 339 tanning, using UK Biobank genetic association data deposited in the IEU Open GWAS 340 Project (53). Since these traits could not conceivably be affected by fatty acids biosynthesis, 341 any evidence for an association between genetic variants and these negative control outcomes 342 would be indicative of residual population stratification(65). Second, we used data from a 343 recent within-sibship GWAS, including up to 178,076 individuals (77,832 sibling pairs) from 344 23 cohorts, to evaluate if our findings are sensitive to population stratification, assortative 345 mating, and indirect genetic effects of parents. We compared the within-sibship association of 346 the selected genetic variants with cardiovascular risk factors (LDL-cholesterol, triglycerides, 347 systolic blood pressure, glycated haemoglobin, smoking, and body mass index) with 348 estimates from standard GWAS models in unrelated individuals (sample size ranging from 349 50,361 for glycated haemoglobin to 155,457 for BMI). Data on cardiovascular disease 350 endpoints and other risk factors (i.e. diastolic blood pressure, fasting glucose, and type 2 351 diabetes) were not available.

352

353 Selection bias

Several processes of sample selection, occurring from study design to data analyses, can result in selected samples not representative of their target populations (e.g. due to case/control ascertainment, participant dropout, loss to follow-up, subgroup analysis, or missing data). In some instances, non-random sample selection can bias inference about the causal effect of an exposure on an outcome, including when using Mendelian randomization (66).

17

360 Although bias can result from multiple selection mechanisms, we were particularly 361 concerned about selection due to ascertainment of cardiovascular disease status given the 362 design of the studies used for cardiovascular disease endpoints. As an example, BioBank 363 Japan is a hospital-based study, in which cases for cardiovascular diseases, except atrial 364 fibrillation, were compared to a control group including a mixture of hospital-based (i.e. 365 individuals diagnosed at health centres with other diseases) and community-based (i.e. 366 individuals from population-based cohorts) controls as previously described (42). In addition, 367 UK Biobank has a response rate of 5.5% and its participants have fewer self-reported health 368 conditions and are more likely to be older, female, wealthier, leaner, non-smokers, non-369 drinkers than the general UK population (67).

To explore whether these processes of sample selection could bias our findings, we adopted a positive exposure control approach in which we used Mendelian randomization to estimate the effect of well-established cardiovascular risk factors (i.e. LDL-cholesterol, triglycerides, systolic, diastolic blood pressure, glucose, type 2 diabetes, smoking, and body mass index) on the risk of cardiovascular diseases. If the effects estimated in the positive control analyses were compatible with what expected and were comparable across data sources, such analyses would argue against selection being a major source of bias.

377

378 **RESULTS**

379

380 Selection of genetic instruments indexing fatty acids biosynthesis

In individuals of European ancestry, the selected genetic variants were rs174546 (*FADS1/2*, chr11q13.3), rs174576 (*FADS1/2*, chr11q13.3), rs3734398 (*ELOVL2*, chr6q15), and rs603424 (*SCD*, chr10q22.1), which explained a proportion of the variance in the

18

384	corresponding marker of enzyme activity of 32.6% (F = 4174) for AA:DGLA, 6.3% (F =
385	580) for GLA:LA, 2.4% (F = 218) for DHA:n-3 DPA, and 1.1% (F = 100) for POA:PA,
386	respectively (Supplementary table 3). The FADS1/2 SNPs (i.e. rs174546 and rs174576)
387	were in strong LD ($R^2 = 0.93$ 1000 Genomes European population), and, therefore, only the
388	SNP more strongly associated with the corresponding marker of enzyme activity was used in
389	subsequent analyses (i.e. rs174546).

In individuals of East Asian ancestry, the top variant in the *FADS1/2* locus was palindromic and, therefore, was replaced by rs174546 (i.e. LD $R^2 = 0.93$ in 1000G East Asian population), which explained 8.4% (F = 125) of the variance in DGLA:LA (**Supplementary table 3**). No genetic variants were associated with markers of D5D activity (AA:DGLA). As previously mentioned, genetic variants at *ELOVL2* and *SCD* loci were not associated with circulating fatty acids in East Asians and, therefore, were not eligible for our analyses, which may be related to the modest sample size available for East Asians (N = 1,361-3,521).

397

398 Impact of genetic instruments on circulating fatty acids

399 Overall, the effect of genetic variants on the fatty acids pool was replicable across 400 studies and ancestries. In addition, the genetic variants impact on the fatty acids pool was 401 consistent with their predicted function on fatty acids biosynthesis. The FADS1/2 SNP 402 (rs174546) was associated with a lower concentration of shorter chain omega-3 (e.g. ALA) 403 and omega-6 (e.g. LA) fatty acids and higher concentration of longer chain omega-3 (e.g. 404 DHA) and omega-6 (e.g. AA) fatty acids. The ELOVL2 SNP (rs3734398) was mostly 405 associated with higher concentration of DHA and lower concentration of eicosapentaenoic 406 acid (EPA) and n-3 DPA, whereas the SCD SNP (rs603424) was related to lower SFA,

19

407 particularly PA, and higher monounsaturated fatty acids (MUFA), particularly POA
408 (Supplementary figures 1 and 2).

409

410 Mendelian randomization analysis

411 In European ancestry individuals, higher FADS1/D5D activity (proxied by increase in 412 AA:DGLA in standard units) was related to higher odds of coronary artery disease (OR =413 1.02; 95% CI: 1.01, 1.03; p-value = 0.006), ischemic stroke (OR = 1.03; 95% CI: 1.01, 1.05; 414 p-value = 0.004), heart failure (OR = 1.02; 95% CI: 1.01, 1.04; p-value = 0.008), atrial 415 fibrillation (OR = 1.02; 95% CI: 1.00, 1.03; p-value = 0.04), peripheral artery disease (OR = 416 1.08; 95% CI: 1.04, 1.12; p-value = 1 x 10^{-5}), venous thromboembolism (OR = 1.07; 95% 417 CI: 1.05, 1.09; p-value = 5 x 10^{-9}), and aortic valve stenosis (OR = 1.08; 95% CI: 1.01, 418 1.15; p-value = 0.02). Only results for ischemic stroke, peripheral artery disease, and venous 419 thromboembolism passed our threshold for multiple testing correction (P < 0.006) (Figure 3). 420 Overall, results were consistent across studies, except for coronary artery disease, for which 421 the estimated effect was attenuated in UK Biobank compared to other studies, and for aortic 422 aneurysm, for which the estimated effect was in different directions between UK Biobank 423 and other studies (Supplementary figure 3).

There was little evidence supporting a relationship between higher *ELOVL2*/ELOVL2 activity (proxied by increase in DHA:DPAn-3 in standard units) and cardiovascular endpoints. However, some results were imprecisely estimated and, therefore, we cannot rule out the presence of clinically meaningful effects, particularly for haemorrhagic stroke (OR = 0.86; 95% CI: 0.71, 1.05; p-value = 0.14) and aortic valve stenosis (OR = 1.17; 95% CI: 0.92, 1.48; p-value = 0.20) (**Figure 3** and **Supplementary figure 3**).

20

430 Higher SCD/SCD activity (proxied by increase in POA:PA in standard units) was 431 related to lower odds of coronary artery disease (OR = 0.82; 95% CI: 0.76, 0.88; p-value = 432 1×10^{-7}) (Figure 3), which was consistent across studies (Supplementary figure 3). There 433 was little evidence supporting a relationship between higher SCD/SCD activity (proxied by 434 increase in POA:PA in standard units) and other cardiovascular endpoints. However, some of 435 these results were imprecisely estimated and, therefore, we cannot rule out the presence of 436 clinically meaningful effects, particularly for peripheral artery disease (OR = 0.85; 95% CI: 437 0.68, 1.06; p-value = 0.14), aortic aneurysm (OR = 1.16; 95% CI: 0.88, 1.52; p-value = 438 (0.30), and a ortic valve stenosis (OR = 0.85; 95% CI: 0.60, 1.22; p-value = 0.38) (Figure 3 439 and **Supplementary figure 3**). 440 In East Asian ancestry individuals, there was limited evidence supporting a

relationship between *FADS2*/D6D activity and the odds of cardiovascular endpoints. However, statistical power was substantially lower for analyses in East Asian individuals and, therefore, some findings could be compatible with higher *FADS2*/D6D activity (proxied by increase in DGLA:LA in standard units) being related to higher odds of disease, such as for atrial fibrillation (OR = 1.02; 95% CI: 0.92, 1.13; p-value = 0.68), or to lower odds of diseases, such as for coronary artery disease (OR = 0.96; 95% CI: 0.91, 1.00; p-value = 0.04) and haemorrhagic stroke (OR = 0.85; 95% CI: 0.75, 0.97; p-value = 0.01) (**Figure 3**).

448

449 Exploring bias in Mendelian randomization analyses

450

451 <u>Horizontal pleiotropy</u>

452

453 Phenome scan

21

In a hypothesis-driven approach, higher D5D/D6D (*FADS1/2*) activity was related to higher LDL-cholesterol, fasting glucose, and type 2 diabetes risk, but lower triglycerides and diastolic blood pressure, among individuals of European (as proxied by AA:DGLA) and East Asian ancestry (as proxied by DGLA:LA). Higher *ELOVL2*/ELOVL2 activity (proxied by DHA:DPAn-3) was not related to cardiovascular risk factors at p-value < 0.00625 and higher *SCD*/SCD activity (proxied by POA:PA) was related to lower LDL-cholesterol, triglycerides, systolic and diastolic blood pressure (**Figure 4**);

461 In the hypothesis-free approach, the FADS1/2 variant (rs174546) was related not only 462 to fatty acids but also to numerous non-fatty acid traits such as lipid, glycaemic, blood cell 463 traits, physical measures (e.g. pulse, heart rate and height), immune-related disorders (e.g. 464 asthma, hypothyroidism, Crohn's disease, inflammatory bowel disease) and several 465 biomarkers (e.g. total bilirubin, insulin growth factor (IGF)-1, cystatin C, alkaline 466 phosphatase and urate) among individuals of European ancestry (Figure 5 and 467 **Supplementary table 4**). The pleiotropic associations of the FADS1/2 variant (rs174546) 468 were also seen in East Asians in relation to lipid, glycaemic, blood cell traits (Figure 5 and 469 **Supplementary table 5**). The *ELOVL2* variant (rs3734398) was related to levels of an 470 unknown metabolite X-12627 and DHA and the SCD variant (rs603424) was related to 471 multiple SFA/MUFA, as well as to bone mineral density and blood cell-related traits (Figure 472 5 and Supplementary table 4).

473

474 Gene expression and tissue-specific analyses

475 Among Europeans, the selected genetic instruments were strongly associated with the 476 expression of the target genes in one or more tissues (N = 208-670 individuals per tissue). 477 The *FADS1* SNP was related to *FADS1* expression in all tissues analysed, whereas the

22

478 ELOVL2 and SCD SNPs were related to expression of ELOVL2 in the liver and expression of 479 SCD in (subcutaneous and visceral) adipose tissues, respectively (Figure 6). This may be 480 partly related to the expression profile of these genes, since FADS1 expression is ubiquitous, 481 whereas *ELOVL2* and *SCD* expressions are more prominent in specific tissues 482 (Supplementary figure 4). As expected, the alleles increasing the expression of the target 483 genes corresponded to the same alleles increasing the rate of fatty acids biosynthesis, as 484 proxied by markers of enzyme activity, across tissues, except for FADS1 expression in whole 485 blood (Figure 6). Regarding expression of non-target genes, the FADS1 SNP was related to 486 expression of eleven other genes, including FADS2, FADS3, TMEM258, MYRF, and FEN1, 487 across multiple tissues, whereas the ELOVL2 SNP was related to the expression of SYCP2L 488 (artery, heart and whole blood tissues) and ELOVL2-AS1 (liver) and the SCD SNP was 489 related to the expression of three other genes, BLOC1S2, PKD2L1 and OLMALINC, in 490 subcutaneous adipose tissue only (Figure 6).

491 The fact that the selected instruments are related to the expression of nearby non-492 target genes, which is specially the case for the FADS1 SNP, could bias our analyses if the 493 proteins encoded by these genes directly influence cardiovascular diseases. To explore that, 494 we used multivariable Mendelian randomization, which supported a direct effect of the target 495 genes (i.e. FADS1, ELOVL2 and SCD) on cardiovascular diseases and risk factors. In 496 Europeans, higher FADS1 expression in multiple tissues (e.g. visceral adipose, artery, heart -497 atrial appendage, liver and pancreas) was related to higher risk of most cardiovascular 498 diseases (Supplementary figure 5A and 5B) and changes in several risk factors, including 499 higher LDL-cholesterol and fasting glucose (Supplementary figure 6A and 6B). Higher 500 expression of SCD in subcutaneous adipose tissue was mostly associated to lower risk of 501 coronary artery disease, heart failure, venous thromboembolism and lower diastolic blood 502 pressure, whereas higher expression of ELOVL2 was related to higher LDL-cholesterol and

23

type 2 diabetes risk (Supplementary figure 5A-B and 6A-B). The conditional F statistics for
these analyses ranged from 18 to 433 and 5 to 50 in unadjusted and adjusted models,
respectively (Supplementary table 6).

506

507 Confounding by linkage disequilibrium

508

509 Genetic colocalization

We used genetic colocalization among Europeans to tease apart whether results from Mendelian randomization analyses were compatible with a shared variant between proxies of enzyme activity (i.e. AA:DGLA, DHA:DPAn-3, and POA:PA) and cardiovascular diseases risk and risk factors, which is a necessary (though not sufficient) condition for two traits to be causally related.

515 For AA:DGLA (proxying D5D activity), there was strong evidence that it colocalised 516 with risk of venous thromboembolism (PPA = 85% for a shared variant). For other 517 cardiovascular disease outcomes, PPA was 0%-27% for a shared variant accompanied by 518 PPA of 60%-100% for the variant being associated with enzyme activity only, which could 519 be a result of limited statistical power (Supplementary table 7 and Supplementary figure 520 7). In addition, the top variant for AA:DGLA (rs174546) was in strong LD with the top 521 variants for peripheral artery disease, venous thromboembolism, ischemic stroke, and heart 522 failure ($\mathbb{R}^2 > 0.8$ using 1000G European population), although in weak/moderate LD with top variants for coronary artery disease, atrial fibrillation, and aortic valve stenosis ($R^2 = 0.19$ -523 524 0.42) (Supplementary table 8). After conditioning the genetic association data for 525 AA:DGLA and venous thromboembolism on rs174546, there was no evidence of a distinct or 526 shared genetic signal (Supplementary table 9).

24

527 There was supportive evidence for a shared causal variant of AA:DGLA with LDL-528 cholesterol (PPA for shared variant = 87%) and for distinct causal variants with systolic, 529 diastolic blood pressure, and triglycerides (PPA for distinct variants = 90-100%). Evidence 530 was less conclusive for colocalization of AA:DGLA with fasting glucose (PPA for shared 531 variant = 64%) (Supplementary table 10 and Supplementary figure 8). The top variant for 532 AA:DGLA (rs174546) was in strong LD with the top variants for LDL-cholesterol, triglycerides and glucose ($R^2 > 0.92$ using 1000G European population) (Supplementary 533 534 table 8).

For POA:PA (proxying *SCD*/SCD activity), there was strong evidence that it colocalised with risk of coronary artery disease (PPA = 99% for a shared variant) (**Supplementary table 7** and **supplementary figure 7**). After conditioning the genetic association data for POA:PA and coronary artery disease on rs603424, there was no evidence of a distinct or shared genetic signal (**Supplementary table 9**).

540 Colocalization analyses supported distinct genetic variants between POA:PA and 541 LDL-cholesterol, triglycerides, systolic, diastolic blood pressure, type2 diabetes and body 542 mass index (PPA for distinct variants = 86-100%) (**Supplementary table 10** and 543 **Supplementary figure 8**).

544

545 <u>Confounding by population stratification, assortative mating and indirect genetic effects</u>

The *FADS1/2* SNP (rs174546) was associated with both negative control outcomes among Europeans: skin colour [mean change of 0.005 unit per C allele (p-value = 5×10^{-5})] and ease of skin tanning [mean change of -0.006 unit per C allele (p-value = 0.007)], while the *SCD* SNP was associated with ease of skin tanning [mean change of -0.006 unit increase per C allele (p-value = 0.037)] (**Supplementary table 11**).

25

551	To explore the potential impact of confounding from population stratification,
552	assortative mating and indirect genetic effects, we compared within-sibship associations of
553	the selected genetic variants with cardiovascular risk factors with estimates from unrelated
554	individuals. Estimates were broadly consistent indicating that our findings are unlikely to
555	have been affected by population stratification, assortative mating or indirect genetic effects
556	(Figure 7). As an example, for the FADS1/2 SNP (rs174546), each C allele was related to a
557	mean LDL-cholesterol increase of 0.041 (95% CI: 0.025; 0.057) and 0.036 (95% CI: 0.025;
558	0.046) SD units within-siblings and in unrelated individuals, respectively.
559	

560 <u>Selection bias</u>

561

562 Positive control analyses

563 Overall, we observed the expected effect of well-established risk factors on the 564 development of cardiovascular diseases across studies (Supplementary figure 9). Systolic, 565 diastolic blood pressure and body mass index were related to higher odds of all 566 cardiovascular disease outcomes in studies of European ancestry individuals (i.e. UK 567 Biobank, genetic association metanalyses and FinnGen) and higher odds of most 568 cardiovascular outcomes (except for coronary and peripheral artery disease) in Biobank Japan. Higher LDL-cholesterol and triglycerides, and liability to type 2 diabetes were related 569 570 to higher odds of coronary artery disease and peripheral artery disease across studies for both 571 ancestries, while glucose and smoking were related to higher odds of peripheral artery disease 572 in Europeans and East Asians. There were a few instances where these risk factors were 573 related to lower odds of disease, such as type 2 diabetes liability with hemorrhagic stroke

26

574 (Biobank Japan) and LDL-cholesterol with hemorrhagic stroke (UK Biobank and Biobank575 Japan).

576

577 **DISCUSSION**

578

579 Main findings

580 In Europeans, our findings indicate that higher PUFA biosynthesis (proxied by 581 FADS1/D5D activity) is related to higher risk of several cardiovascular diseases (and risk 582 factors), while higher MUFA biosynthesis (proxied by SCD/SCD activity) is related to lower 583 risk of coronary artery disease. In addition, despite the strong LD in the FADS1/2 region, our 584 results indicate that the relation between PUFA biosynthesis and cardiovascular diseases is 585 driven by changes in FADS1 (not FADS2) expression among Europeans. In East Asians, the 586 same FADS1/2 variant was related to similar pleiotropic effects on the phenome (e.g. lipid, 587 glycaemic, blood cell traits) compared to Europeans, although the relation with 588 cardiovascular diseases was unclear as most effect estimates were either imprecisely 589 estimated (e.g. atrial fibrillation) or, for coronary artery disease, in the opposite direction in 590 East Asians compared to results in Europeans.

By triangulating multiple approaches, our results are compatible with higher LDLcholesterol (and possibly glucose) being a downstream effect of higher *FADS1*/D5D activity instead of explained by confounding by LD or by the co-expression of other genes in the region. Given the well-established role of *FADS1*/D5D activity in PUFA biosynthesis and the well-known involvement of LDL-cholesterol in the aetiology of multiple cardiovascular diseases, this strengthens the evidence for a causal relationship and provides a putative mediating pathway for the effect of PUFA biosynthesis on the risk of cardiovascular diseases.

27

598

599 *Previous literature*

The relation between fatty acids and cardiovascular diseases has been explored in classical observational studies, randomized controlled trials and Mendelian randomization studies. Most previous studies have focused on coronary artery disease and, to a lesser extent, on stroke; therefore, other types of cardiovascular disease endpoints, such as heart failure and atrial fibrillation, remain under explored

605 Previous meta-analyses of classical observational studies indicate that higher 606 circulating long-chain omega-3 and omega-6 PUFA are either not associated or are associated 607 with lower risk of coronary artery disease and stroke (68-72), whereas higher circulating 608 MUFA and SFA are either not associated or are associated with higher risk of coronary artery 609 disease and stroke (68, 69). Recent systematic reviews of randomized controlled trials of 610 dietary advice or supplementation of omega-3 and omega-6 PUFA have suggested little to no 611 benefit in reducing the risk of cardiovascular diseases (73-75). However, most studies 612 included in these systematic reviews were at moderate to high risk of bias and there is large 613 uncertainty on the evidence linking PUFA to some cardiovascular outcomes (73-75). It is 614 important to emphasise that comparing our findings to previous classical observational and 615 randomized controlled trials deserves caution as our genetic instruments have a broad impact 616 on the fatty acids pool and, therefore, cannot be used to make inferences about individual 617 fatty acids/fatty acids classes. As an example, higher FADS1/D5D activity (instrumented by 618 rs174546) is related to higher longer chain omega-3 and omega-6 PUFA (e.g. AA, EPA and 619 DHA) but lower shorter chain omega-3 and omega-6 PUFA (e.g. LA and ALA).

620 Several GWAS have reported that SNPs within the *FADS1/2* locus are associated with 621 cardiovascular risk factors (e.g. LDL-cholesterol and triglycerides) (19, 76, 77) and previous

28

622 Mendelian randomization studies have reported that longer and shorter chain PUFA are 623 related to risk of cardiovascular diseases in contrasting directions among Europeans, 624 including coronary artery disease in CARDIoGRAMplusC4D and UK Biobank (26, 27, 78), 625 ischemic stroke in MEGASTROKE and UK Biobank (28, 29), and venous thromboembolism 626 in UK Biobank (29). Our findings expand on previous Mendelian randomization studies by 627 implicating higher FADS1/D5D activity in the development of a wide range of cardiovascular 628 diseases among Europeans in the largest available samples to date (up to 1,153,768 629 individuals). In addition, to our knowledge, this is the first Mendelian randomization study to 630 report a potential protective effect of higher SCD activity on coronary artery disease among 631 Europeans and to explore the relation between FADS2/D6D activity and cardiovascular 632 diseases among East Asians.

633

634 Plausibility of Mendelian randomization assumptions

A major challenge in Mendelian randomization studies is the unprovable assumption that the estimated effect of the genetic instrument on the outcome is mediated by the exposure, and not biased by horizontal pleiotropy, population stratification, assortative mating, indirect genetic effects or selection bias (59, 66, 79). We assessed the plausibility that our findings were explained by these sources of bias through a series of sensitivity analyses.

To mitigate bias due to horizontal pleiotropy (i.e. the genetic instrument influences exposure and outcome via independent pathways), we have restricted our analyses to genetic variants near genes with well-established role in fatty acids biosynthesis. We have confirmed that these variants have the expected impact on the circulating fatty acids pool and on the expression of the target genes in key tissues (except for *FADS1* in whole blood). Previous evidence confirms that the selected *FADS1/2* and *SCD* variants, or variants in high LD, are

29

646 related to changes in fatty acids composition across multiple sites, including adipose tissue 647 (80-82), brain (83) and liver (84). Genetic colocalization and multivariable Mendelian 648 randomization (adjusting for co-expressed genes in the region) supported a causal relation 649 between D5D activity, venous thromboembolism and LDL-cholesterol, and between SCD 650 activity and coronary artery disease. It is important to note that we were likely underpowered 651 to test colocalization between fatty acids biosynthesis and cardiovascular disease outcomes. 652 Where there was evidence that the selected genetic variant was associated with the expression 653 of non-target genes in the region in a given tissue, findings from multivariable Mendelian 654 randomization were consistent with expression of the target gene (i.e. FADSI) having direct 655 effects on the outcome.

656 Confounding could be introduced in Mendelian randomization studies due to 657 population stratification, assortative mating and indirect genetic effects. Of these factors, 658 population stratification is likely to be of the most concern for this study (59). Despite 659 attempts to control for population structure in genetic association data, there could still be 660 residual population structure (63). We showed that within-sibship associations of FADS1/2, 661 ELOVL2, and SCD variants with established cardiovascular risk factors were broadly similar 662 to estimates from unrelated individuals, suggesting that our results are unlikely to be affected 663 by population stratification, assortative mating or indirect genetic effects of parents.

Non-random sample selection may introduce bias in Mendelian randomization studies especially if the mechanism of selection depends on the exposure and/or outcome (66, 85). Using a positive control approach, we were able to identify the expected effect of wellestablished risk factors on cardiovascular diseases across studies contributing with data on cardiovascular disease endpoints, which is reassuring given our concerns that case-control ascertainment could introduce bias in the analyses. Although results from the positive control approach argues against selection being a major source of bias in this study, we cannot fully

30

671 rule out that selection might have introduced some bias in our analyses as bias due to 672 selection will depend on context-specific causal structures underlying the data under 673 consideration.

674

675 Implications

Our findings are supportive of the involvement of fatty acids biosynthesis in the aetiology of cardiovascular diseases and highlight D5D and SCD as potential targets for the prevention of these diseases. Further work is needed to understand the precise underlying mechanism(s) are required.

680 The relation between D5D activity and cardiovascular diseases is plausibly mediated 681 by one or more fatty acids involved in the PUFA biosynthesis pathway. Given the ubiquitous 682 impact of higher D5D activity on the circulating PUFA pool, we cannot pinpoint which 683 specific fatty acids are driving these effects. For illustration, higher D5D activity decreases 684 LA and ALA (and other omega-3 and omega-6 PUFA upstream of the reaction catalysed by 685 D5D). Lower LA may relate to unfavourable metabolic changes, such as higher plasma LDL-686 cholesterol, apolipoprotein B, and triglycerides, and haemoglobin A1c (2, 86) and, therefore, 687 is a plausible mediator of the relation between higher D5D activity and higher cardiovascular 688 diseases risk. On the other hand, higher D5D activity increases long-chain PUFA such as AA, 689 which influences key membrane/tissue functions, such as membrane fluidity, the activity of 690 membrane-bound receptors, transport proteins and signal transmission (87), and is a 691 precursor for eicosanoids (e.g. prostaglandins, leukotrienes, and thromboxane), which are 692 involved in inflammation, platelet aggregation and vascular remodeling (88).

693 The putative mechanisms underpinning the relation SCD activity and coronary artery 694 disease in humans are unclear. *Scd-1* deficient rodents are protected against diet-induced

31

695	obesity, insulin resistance, and hepatic steatosis (89-91), but show increased inflammation
696	and atherogenesis (91, 92). The putative protective effect of higher SCD activity on coronary
697	artery disease might be related to lower availability of palmitic acid and consequent lower
698	production of its toxic metabolites, such as ceramides (93).
699	
700	Conclusions
701	We found supportive evidence for an involvement of PUFA and MUFA biosynthesis
702	in the aetiology of cardiovascular diseases. Our study illustrates the power of integrating

- 703 multiple approaches to improve causal inference on the role of modifiable risk factors in the
- 704 development of cardiovascular diseases.

32

706 Supplemental information description

- Supplementary methods
- Supplementary tables 1 to 10
- Supplementary figures 1 to 9
- 710

711 Acknowledgements

712

713 We want to acknowledge participants and investigators from FinnGen study, UK 714 Biobank, Biobank Japan, and the multiple large-scale GWAS consortia which made summary 715 data available, including CARDIoGRAMplusC4D, MEGASTROKE, HERMES, atrial 716 fibrillation GWAS metanalysis, aortic aneurysm GWAS metanalysis, CHARGE, and the 717 Within Family Consortium. This work was carried out using UK Biobank project 15825. 718 Data on coronary artery disease have been contributed by CARDIoGRAMplusC4D 719 investigators and have been downloaded from www.CARDIOGRAMPLUSC4D.ORG'. The 720 MEGASTROKE project received funding from sources specified at 721 http://www.megastroke.org/acknowledgments.html (a list of all MEGASTROKE authors can 722 be found in the appendix A - Supplementary methods). This work was carried out using the 723 computational facilities of the Advanced Computing Research Centre, University of Bristol -724 http://www.bristol.ac.uk/acrc/. Quality Control filtering of the UK Biobank data was 725 conducted by R.Mitchell, G.Hemani, T.Dudding, L.Corbin, S.Harrison, L.Paternoster as 726 described in the published protocol (doi: 10.5523/bris.1ovaau5sxunp2cv8rcy88688v). The 727 MRC IEU UK Biobank GWAS pipeline was developed by B.Elsworth, R.Mitchell, 728 C.Raistrick, L.Paternoster, G.Hemani, T.Gaunt (doi: 729 10.5523/bris.pnoat8cxo0u52p6ynfaekeigi).

730

731 Sources of funding

732

MCB was supported by a UK Medical Research Council (MRC) Skills Development Fellowship (MR/P014054/1). MCB and DAL are supported by the British Heart Foundation (AA/18/7/34219) and DAL is supported by a British Heart Foundation Chair (CH/F/20/90003). MCB, PH, JZ, GH, LJH, TRG, GDS, and DAL work in a Unit receives funding from the University of Bristol and UK Medical Research Council (MRC)

33

(MC_UU_00011/1, MC_UU_00011/4 and MC_UU_00011/6). PCH was supported by Cancer Research UK (C52724/A20138 & C18281/A29019). MVH works in a unit that receives funding from the UK Medical Research Council and is supported by a British Heart Foundation Intermediate Clinical Research Fellowship (FS/18/23/33512) and the National Institute for Health Research Oxford Biomedical Research Centre. The funders had no role in the design, analyses, interpretation of results or writing of the paper. The views expressed in this paper are those of the authors and not necessarily any of the funders.

- 745
- 746 **Declaration of interests**
- 747

DAL receives support from several national and international government and charitable research funders, as well as from Medtronic Ltd and Roche Diagnostics for research unrelated to that presented here. TRG receives funding from Biogen for work unrelated to that presented here. MVH has consulted for Boehringer Ingelheim, and in adherence to the University of Oxford's Clinical Trial Service Unit & Epidemiological Studies Unit (CSTU) staff policy, did not accept personal honoraria or other payments from pharmaceutical companies.

- All other authors declare no competing interests.
- 756

757 Web resources

- 758 Coloc: https://cran.r-project.org/web/packages/coloc/index.html
- 759 GWIS: https://sites.google.com/site/mgnivard/gwis
- 760 IEU Open GWAS Project: https://gwas.mrcieu.ac.uk/
- 761 MVMR R package: https://github.com/WSpiller/MVMR
- 762 PWCoCco: https://github.com/jwr-git/pwcoco
- 763 TwoSampleMR R package: https://mrcieu.github.io/TwoSampleMR
- 764

765 Data availability

766

Genetic association data on fatty acids, cardiovascular diseases (CVDs) and CVDs
risk factors are publicly available or available on request from original investigators as
detailed in Supplementary tables 1 and 2.

771	References
772	
773	1 Ratnayake, W.M. and Galli, C. (2009) Fat and fatty acid terminology, methods of analysis and
774	fat digestion and metabolism: a background review paper. Ann Nutr Metab, 55, 8-43.
775	2 Mensink, R.P., Zock, P.L., Kester, A.D. and Katan, M.B. (2003) Effects of dietary fatty acids
776	and carbohydrates on the ratio of serum total to HDL cholesterol and on serum lipids and
777	apolipoproteins: a meta-analysis of 60 controlled trials. Am J Clin Nutr, 77, 1146-1155.
778	Balk, E.M., Lichtenstein, A.H., Chung, M., Kupelnick, B., Chew, P. and Lau, J. (2006) Effects of
779	omega-3 fatty acids on serum markers of cardiovascular disease risk: a systematic review.
780	Atherosclerosis, 189 , 19-30.
781	4 Hooper, L., Summerbell, C.D., Thompson, R., Sills, D., Roberts, F.G., Moore, H.J. and Davey
782	Smith, G. (2012) Reduced or modified dietary fat for preventing cardiovascular disease. Cochrane
783	Database Syst Rev, in press., CD002137.
784	5 Sanders, T.A. (2009) Fat and fatty acid intake and metabolic effects in the human body. <i>Ann</i>
785	Nutr Metab, 55 , 162-172.
786	6 Schwingshackl, L., Strasser, B. and Hoffmann, G. (2011) Effects of monounsaturated fatty
787	acids on glycaemic control in patients with abnormal glucose metabolism: a systematic review and
788	meta-analysis. Ann Nutr Metab, 58 , 290-296.
789	7 Miller, P.E., Van Elswyk, M. and Alexander, D.D. (2014) Long-chain omega-3 fatty acids
790	eicosapentaenoic acid and docosahexaenoic acid and blood pressure: a meta-analysis of randomized
791	controlled trials. Am J Hypertens, 27 , 885-896.
792	8 Shah, M., Adams-Huet, B. and Garg, A. (2007) Effect of high-carbohydrate or high-cis-
793	monounsaturated fat diets on blood pressure: a meta-analysis of intervention trials. Am J Clin Nutr,
794	85 , 1251-1256.
795	9 Mozaffarian, D. and Wu, J.H. (2011) Omega-3 fatty acids and cardiovascular disease: effects
796	on risk factors, molecular pathways, and clinical events. J Am Coll Cardiol, 58, 2047-2067.
797	10 Masson, C.J. and Mensink, R.P. (2011) Exchanging saturated fatty acids for (n-6)
798	polyunsaturated fatty acids in a mixed meal may decrease postprandial lipemia and markers of
799	inflammation and endothelial activity in overweight men. J Nutr, 141, 816-821.
800	Schwartz, E.A., Zhang, W.Y., Karnik, S.K., Borwege, S., Anand, V.R., Laine, P.S., Su, Y. and
801	Reaven, P.D. (2010) Nutrient modification of the innate immune response: a novel mechanism by
802	which saturated fatty acids greatly amplify monocyte inflammation. Arterioscler Thromb Vasc Biol,
803	30 , 802-808.
804	Sampath, H. and Ntambi, J.M. (2005) Polyunsaturated fatty acid regulation of genes of lipid
805	metabolism. <i>Annu Rev Nutr, 25,</i> 317-340.
806	Pase, M.P., Grima, N.A. and Sarris, J. (2011) Do long-chain n-3 fatty acids reduce arterial
807	stiffness? A meta-analysis of randomised controlled trials. <i>Br J Nutr</i> , 106 , 974-980.
808	Jakobsson, A., Westerberg, R. and Jacobsson, A. (2006) Fatty acid elongases in mammals:
809	their regulation and roles in metabolism. Prog Lipid Res, 45, 237-249.
810	Lemaitre, R.N., Tanaka, T., Tang, W., Manichaikul, A., Foy, M., Kabagambe, E.K., Nettleton,
811	J.A., King, I.B., Weng, L.C., Bhattacharya, S. et al. (2011) Genetic loci associated with plasma
812	phospholipid n-3 fatty acids: a meta-analysis of genome-wide association studies from the CHARGE
813	Consortium. PLoS Genet, 7 , e1002193.
814	Guan, W., Steffen, B.T., Lemaitre, R.N., Wu, J.H., Tanaka, T., Manichaikul, A., Foy, M., Rich,
815	S.S., Wang, L., Nettleton, J.A. <i>et al.</i> (2014) Genome-wide association study of plasma N6
816	polyunsaturated fatty acids within the cohorts for heart and aging research in genomic epidemiology
817	consortium. Circ Cardiovasc Genet, 7, 321-331.
818	Wu, J.H., Lemaitre, R.N., Manichaikul, A., Guan, W., Tanaka, T., Foy, M., Kabagambe, E.K.,
819	Djousse, L., Siscovick, D., Fretts, A.M. <i>et al.</i> (2013) Genome-wide association study identifies novel
820	loci associated with concentrations of four plasma phospholipid fatty acids in the de novo

821	lipogenesis pathway: results from the Cohorts for Heart and Aging Research in Genomic
822	Epidemiology (CHARGE) consortium. Circ Cardiovasc Genet, 6, 171-183.
823	Shin, S.Y., Fauman, E.B., Petersen, A.K., Krumsiek, J., Santos, R., Huang, J., Arnold, M., Erte, I.,
824	Forgetta, V., Yang, T.P. <i>et al.</i> (2014) An atlas of genetic influences on human blood metabolites. <i>Nat</i>
825	Genet, 46 , 543-550.
826	19 Kettunen, J., Demirkan, A., Wurtz, P., Draisma, H.H., Haller, T., Rawal, R., Vaarhorst, A.,
827	Kangas, A.J., Lyytikainen, L.P., Pirinen, M. <i>et al.</i> (2016) Genome-wide study for circulating
828	metabolites identifies 62 loci and reveals novel systemic effects of LPA. <i>Nat Commun</i> , 7, 11122.
829	20 Tintle, N.L., Pottala, J.V., Lacey, S., Ramachandran, V., Westra, J., Rogers, A., Clark, J., Olthoff,
830	B., Larson, M., Harris, W. et al. (2015) A genome-wide association study of saturated, mono- and
831	polyunsaturated red blood cell fatty acids in the Framingham Heart Offspring Study. Prostaglandins
832	Leukot Essent Fatty Acids, 94 , 65-72.
833	21 Dorajoo, R., Sun, Y., Han, Y., Ke, T., Burger, A., Chang, X., Low, H.Q., Guan, W., Lemaitre, R.N.,
834	Khor, C.C. <i>et al.</i> (2015) A genome-wide association study of n-3 and n-6 plasma fatty acids in a
835	Singaporean Chinese population. Genes Nutr, 10, 53.
836	22 Ebrahim, S. and Davey Smith, G. (2008) Mendelian randomization: can genetic epidemiology
837	help redress the failures of observational epidemiology? Hum Genet, 123 , 15-33.
838	Hingorani, A. and Humphries, S. (2005) Nature's randomised trials. <i>Lancet</i> , 366 , 1906-1908.
839	Smith, G.D., Lawlor, D.A., Harbord, R., Timpson, N., Day, I. and Ebrahim, S. (2007) Clustered
840	environments and randomized genes: a fundamental distinction between conventional and genetic
841	epidemiology. PLoS Med, 4 , e352.
842	25 Holmes, M.V., Ala-Korpela, M. and Smith, G.D. (2017) Mendelian randomization in
843	cardiometabolic disease: challenges in evaluating causality. Nat Rev Cardiol, 14, 577-590.
844	Jager, S., Cuadrat, R., Hoffmann, P., Wittenbecher, C. and Schulze, M.B. (2020) Desaturase
845	Activity and the Risk of Type 2 Diabetes and Coronary Artery Disease: A Mendelian Randomization
846	Study. Nutrients, 12.
847	27 Liao, L.Z., Li, W.D., Liu, Y., Li, J.P., Zhuang, X.D. and Liao, X.X. (2020) Exploring the causal
848	pathway from omega-6 levels to coronary heart disease: A network Mendelian randomization study.
849	Nutr Metab Cardiovasc Dis, 30 , 233-240.
850	28 Yuan, T., Si, S., Li, Y., Li, W., Chen, X., Liu, C., Li, J., Wang, B., Hou, L., Liu, Y. <i>et al.</i> (2020) Roles
851	for circulating polyunsaturated fatty acids in ischemic stroke and modifiable factors: a Mendelian
852	randomization study. <i>Nutr J, 19</i> , 70.
853	29 Yuan, S., Back, M., Bruzelius, M., Mason, A.M., Burgess, S. and Larsson, S. (2019) Plasma
854	Phospholipid Fatty Acids, FADS1 and Risk of 15 Cardiovascular Diseases: A Mendelian Randomisation
855	Study. Nutrients, 11.
856	30 Zhang, T., Zhao, J.V. and Schooling, C.M. (2021) The associations of plasma phospholipid
857	arachidonic acid with cardiovascular diseases: A Mendelian randomization study. EBioMedicine, 63,
858	103189.
859	31 Chen, H.Y., Cairns, B.J., Small, A.M., Burr, H.A., Ambikkumar, A., Martinsson, A., Theriault, S.,
860	Munter, H.M., Steffen, B., Zhang, R. et al. (2020) Association of FADS1/2 Locus Variants and
861	Polyunsaturated Fatty Acids With Aortic Stenosis. JAMA Cardiol, 5, 694-702.
862	32 Yuan, S. and Larsson, S.C. (2019) Plasma Phospholipid Fatty Acids and Risk of Atrial
863	Fibrillation: A Mendelian Randomization Study. Nutrients, 11.
864	Holmes, M.V., Richardson, I.G., Ference, B.A., Davies, N.M. and Davey Smith, G. (2021)
805	Integrating genomics with biomarkers and therapeutic targets to invigorate cardiovascular drug
800 867	development. <i>Nat Rev Caralol</i> , 18 , 435-453.
00/ 969	54 INIKPAY, IVI., GOEI, A., WON, H.H., HAII, L.IVI., WIIIEnborg, C., Kanoni, S., Saleneen, D., Kyriakou, T. Nalson, C.B. Hanawall, J.C. et al. (2015) A comprehensive 1,000 Concernes based examples with
000 860	i., iverson, c.r., hopeweil, J.C. <i>et al.</i> (2015) A comprehensive 1,000 Genomes-based genome-Wide
009 870	association meta-analysis of coronary aftery disease. <i>Nat Genet</i> , 47 , 1121-1150.
07U 871	J. Gioro A.K. van der Laan S.W. Gretaredettin S. et al. (2018) Multiansectry genome wide
0/1	L., Olese, A.K., Vali dei Laan, S.W., Orelaisuollir, S. et al. (2016) Multiancestry genome-wide

36

872 association study of 520,000 subjects identifies 32 loci associated with stroke and stroke subtypes. 873 Nat Genet, 50, 524-537. 874 36 Nielsen, J.B., Thorolfsdottir, R.B., Fritsche, L.G., Zhou, W., Skov, M.W., Graham, S.E., Herron, 875 T.J., McCarthy, S., Schmidt, E.M., Sveinbjornsson, G. et al. (2018) Biobank-driven genomic discovery 876 yields new insight into atrial fibrillation biology. Nat Genet, 50, 1234-1239. 877 37 Jones, G.T., Tromp, G., Kuivaniemi, H., Gretarsdottir, S., Baas, A.F., Giusti, B., Strauss, E., 878 Van't Hof, F.N., Webb, T.R., Erdman, R. et al. (2017) Meta-Analysis of Genome-Wide Association 879 Studies for Abdominal Aortic Aneurysm Identifies Four New Disease-Specific Risk Loci. Circ Res, 120, 880 341-353. 881 Shah, S., Henry, A., Roselli, C., Lin, H., Sveinbjornsson, G., Fatemifar, G., Hedman, A.K., Wilk, 38 882 J.B., Morley, M.P., Chaffin, M.D. et al. (2020) Genome-wide association and Mendelian 883 randomisation analysis provide insights into the pathogenesis of heart failure. Nat Commun, 11, 163. 884 39 Sudlow, C., Gallacher, J., Allen, N., Beral, V., Burton, P., Danesh, J., Downey, P., Elliott, P., 885 Green, J., Landray, M. et al. (2015) UK biobank: an open access resource for identifying the causes of 886 a wide range of complex diseases of middle and old age. PLoS Med, 12, e1001779. 887 Allen, N.E., Sudlow, C., Peakman, T., Collins, R. and Biobank, U.K. (2014) UK biobank data: 40 888 come and get it. Sci Transl Med, 6, 224ed224. 889 41 FinnGen. (2020), in press. 890 42 Nagai, A., Hirata, M., Kamatani, Y., Muto, K., Matsuda, K., Kiyohara, Y., Ninomiya, T., 891 Tamakoshi, A., Yamagata, Z., Mushiroda, T. et al. (2017) Overview of the BioBank Japan Project: 892 Study design and profile. J Epidemiol, 27, S2-S8. 893 43 Hirata, M., Kamatani, Y., Nagai, A., Kiyohara, Y., Ninomiya, T., Tamakoshi, A., Yamagata, Z., 894 Kubo, M., Muto, K., Mushiroda, T. et al. (2017) Cross-sectional analysis of BioBank Japan clinical 895 data: A large cohort of 200,000 patients with 47 common diseases. J Epidemiol, 27, S9-S21. 896 44 Ishigaki, K., Akiyama, M., Kanai, M., Takahashi, A., Kawakami, E., Sugishita, H., Sakaue, S., 897 Matoba, N., Low, S.K., Okada, Y. et al. (2020) Large-scale genome-wide association study in a 898 Japanese population identifies novel susceptibility loci across different diseases. Nat Genet, 52, 669-899 679. 900 45 Low, S.K., Takahashi, A., Ebana, Y., Ozaki, K., Christophersen, I.E., Ellinor, P.T., Consortium, 901 A.F., Ogishima, S., Yamamoto, M., Satoh, M. et al. (2017) Identification of six new genetic loci 902 associated with atrial fibrillation in the Japanese population. *Nat Genet*, **49**, 953-958. 903 46 Zhu, J., Manichaikul, A., Hu, Y., Chen, Y.I., Liang, S., Steffen, L.M., Rich, S.S., Tsai, M., 904 Siscovick, D.S., Lemaitre, R.N. et al. (2017) Meta-analysis of genome-wide association studies 905 identifies three novel loci for saturated fatty acids in East Asians. Eur J Nutr, 56, 1477-1484. 906 47 Hu, Y., Tanaka, T., Zhu, J., Guan, W., Wu, J.H.Y., Psaty, B.M., McKnight, B., King, I.B., Sun, Q., 907 Richard, M. et al. (2017) Discovery and fine-mapping of loci associated with MUFAs through trans-908 ethnic meta-analysis in Chinese and European populations. J Lipid Res, 58, 974-981. 909 Nieuwboer, H.A., Pool, R., Dolan, C.V., Boomsma, D.I. and Nivard, M.G. (2016) GWIS: 48 910 Genome-Wide Inferred Statistics for Functions of Multiple Phenotypes. Am J Hum Genet, 99, 917-911 927. 912 49 Burgess, S., Davies, N.M. and Thompson, S.G. (2016) Bias due to participant overlap in two-913 sample Mendelian randomization. Genet Epidemiol, 40, 597-608. 914 Hemani, G., Zheng, J., Elsworth, B., Wade, K.H., Haberland, V., Baird, D., Laurin, C., Burgess, 50 915 S., Bowden, J., Langdon, R. et al. (2018) The MR-Base platform supports systematic causal inference 916 across the human phenome. Elife, 7. 917 Pickrell, J.K., Berisa, T., Liu, J.Z., Segurel, L., Tung, J.Y. and Hinds, D.A. (2016) Detection and 51 918 interpretation of shared genetic influences on 42 human traits. Nat Genet, 48, 709-717. 919 Yang, Q., Sanderson, E., Tilling, K., Borges, M.C. and Lawlor, D.A. (2019) Exploring and 52 920 mitigating potential bias when genetic instrumental variables are associated with multiple non-921 exposure traits in Mendelian randomization. medRxiv, in press., 19009605.

922 53 Elsworth, B., Lyon, M., Alexander, T., Liu, Y., Matthews, P., Hallett, J., Bates, P., Palmer, T., 923 Haberland, V., Smith, G.D. et al. (2020) The MRC IEU OpenGWAS data infrastructure. bioRxiv, in 924 press., 2020.2008.2010.244293. 925 54 Sanderson, E., Davey Smith, G., Windmeijer, F. and Bowden, J. (2018) An examination of 926 multivariable Mendelian randomization in the single-sample and two-sample summary data settings. 927 Int J Epidemiol, in press. 928 Giambartolomei, C., Vukcevic, D., Schadt, E.E., Franke, L., Hingorani, A.D., Wallace, C. and 55 929 Plagnol, V. (2014) Bayesian test for colocalisation between pairs of genetic association studies using 930 summary statistics. PLoS Genet, 10, e1004383. 931 Yang, J., Lee, S.H., Goddard, M.E. and Visscher, P.M. (2011) GCTA: a tool for genome-wide 56 932 complex trait analysis. Am J Hum Genet, 88, 76-82. 933 Yang, J., Ferreira, T., Morris, A.P., Medland, S.E., Genetic Investigation of, A.T.C., Replication, 57 934 D.I.G., Meta-analysis, C., Madden, P.A., Heath, A.C., Martin, N.G. et al. (2012) Conditional and joint 935 multiple-SNP analysis of GWAS summary statistics identifies additional variants influencing complex 936 traits. Nat Genet, 44, 369-375, S361-363. 937 Young, A.I., Benonisdottir, S., Przeworski, M. and Kong, A. (2019) Deconstructing the sources 58 938 of genotype-phenotype associations in humans. *Science*, **365**, 1396-1400. 939 Morris, T.T., Davies, N.M., Hemani, G. and Smith, G.D. (2020) Population phenomena inflate 59 940 genetic associations of complex social traits. Sci Adv, 6, eaay0328. 941 Hartwig, F.P., Davies, N.M. and Davey Smith, G. (2018) Bias in Mendelian randomization due 60 942 to assortative mating. *Genet Epidemiol.* **42**, 608-620. 943 Davies, N.M., Howe, L.J., Brumpton, B., Havdahl, A., Evans, D.M. and Davey Smith, G. (2019) 61 944 Within family Mendelian randomization studies. Hum Mol Genet, 28, R170-R179. 945 Ameur, A., Enroth, S., Johansson, A., Zaboli, G., Igl, W., Johansson, A.C., Rivas, M.A., Daly, 62 946 M.J., Schmitz, G., Hicks, A.A. et al. (2012) Genetic adaptation of fatty-acid metabolism: a human-947 specific haplotype increasing the biosynthesis of long-chain omega-3 and omega-6 fatty acids. Am J 948 Hum Genet, 90, 809-820. 949 63 Lawson, D.J., Davies, N.M., Haworth, S., Ashraf, B., Howe, L., Crawford, A., Hemani, G., Davey 950 Smith, G. and Timpson, N.J. (2020) Is population structure in the genetic biobank era irrelevant, a 951 challenge, or an opportunity? Hum Genet, 139, 23-41. 952 Hartwig, F.P., Davies, N.M., Horta, B.L., Ahluwalia, T.S., Bisgaard, H., Bonnelykke, K., Caspi, 64 953 A., Moffitt, T.E., Poulton, R., Sajjad, A. et al. (2019) Effect modification of FADS2 polymorphisms on 954 the association between breastfeeding and intelligence: results from a collaborative meta-analysis. 955 Int J Epidemiol, 48, 45-57. 956 65 Sanderson, E., Richardson, T.G., Hemani, G. and Davey Smith, G. (2021) The use of negative 957 control outcomes in Mendelian randomization to detect potential population stratification. Int J 958 Epidemiol, in press. 959 Hughes, R.A., Davies, N.M., Davey Smith, G. and Tilling, K. (2019) Selection Bias When 66 960 Estimating Average Treatment Effects Using One-sample Instrumental Variable Analysis. 961 Epidemiology, 30, 350-357. 962 67 Fry, A., Littlejohns, T.J., Sudlow, C., Doherty, N., Adamska, L., Sprosen, T., Collins, R. and 963 Allen, N.E. (2017) Comparison of Sociodemographic and Health-Related Characteristics of UK 964 Biobank Participants With Those of the General Population. Am J Epidemiol, 186, 1026-1034. 965 68 Borges, M.C., Schmidt, A.F., Jefferis, B., Wannamethee, S.G., Lawlor, D.A., Kivimaki, M., 966 Kumari, M., Gaunt, T.R., Ben-Shlomo, Y., Tillin, T. et al. (2020) Circulating Fatty Acids and Risk of 967 Coronary Heart Disease and Stroke: Individual Participant Data Meta-Analysis in Up to 16 126 968 Participants. J Am Heart Assoc, 9, e013131. 969 Chowdhury, R., Warnakula, S., Kunutsor, S., Crowe, F., Ward, H.A., Johnson, L., Franco, O.H., 69 970 Butterworth, A.S., Forouhi, N.G., Thompson, S.G. et al. (2014) Association of dietary, circulating, and 971 supplement fatty acids with coronary risk: a systematic review and meta-analysis. Ann Intern Med, 972 160, 398-406.

38

973 70 Chowdhury, R., Stevens, S., Gorman, D., Pan, A., Warnakula, S., Chowdhury, S., Ward, H., 974 Johnson, L., Crowe, F., Hu, F.B. et al. (2012) Association between fish consumption, long chain 975 omega 3 fatty acids, and risk of cerebrovascular disease: systematic review and meta-analysis. BMJ, 976 345. e6698. 977 Iso, H., Sato, S., Umemura, U., Kudo, M., Koike, K., Kitamura, A., Imano, H., Okamura, T., 71 978 Naito, Y. and Shimamoto, T. (2002) Linoleic acid, other fatty acids, and the risk of stroke. Stroke, 33, 979 2086-2093. 980 72 Marklund, M., Wu, J.H.Y., Imamura, F., Del Gobbo, L.C., Fretts, A., de Goede, J., Shi, P., Tintle, 981 N., Wennberg, M., Aslibekyan, S. et al. (2019) Biomarkers of Dietary Omega-6 Fatty Acids and 982 Incident Cardiovascular Disease and Mortality. Circulation, 139, 2422-2436. 983 73 Abdelhamid, A.S., Martin, N., Bridges, C., Brainard, J.S., Wang, X., Brown, T.J., Hanson, S., 984 Jimoh, O.F., Ajabnoor, S.M., Deane, K.H. et al. (2018) Polyunsaturated fatty acids for the primary and 985 secondary prevention of cardiovascular disease. Cochrane Database Syst Rev, 7, CD012345. 986 74 Hooper, L., Al-Khudairy, L., Abdelhamid, A.S., Rees, K., Brainard, J.S., Brown, T.J., Ajabnoor, 987 S.M., O'Brien, A.T., Winstanley, L.E., Donaldson, D.H. et al. (2018) Omega-6 fats for the primary and 988 secondary prevention of cardiovascular disease. Cochrane Database Syst Rev, 7, CD011094. 989 75 Abdelhamid, A.S., Brown, T.J., Brainard, J.S., Biswas, P., Thorpe, G.C., Moore, H.J., Deane, 990 K.H., Summerbell, C.D., Worthington, H.V., Song, F. et al. (2020) Omega-3 fatty acids for the primary 991 and secondary prevention of cardiovascular disease. Cochrane Database Syst Rev, 3, CD003177. 992 76 Aulchenko, Y.S., Ripatti, S., Lindqvist, I., Boomsma, D., Heid, I.M., Pramstaller, P.P., Penninx, 993 B.W., Janssens, A.C., Wilson, J.F., Spector, T. et al. (2009) Loci influencing lipid levels and coronary 994 heart disease risk in 16 European population cohorts. Nat Genet, 41, 47-55. 995 Kathiresan, S., Willer, C.J., Peloso, G.M., Demissie, S., Musunuru, K., Schadt, E.E., Kaplan, L., 77 996 Bennett, D., Li, Y., Tanaka, T. et al. (2009) Common variants at 30 loci contribute to polygenic 997 dyslipidemia. Nat Genet, 41, 56-65. 998 78 Park, S., Lee, S., Kim, Y., Lee, Y., Kang, M., Kim, K., Kim, Y., Han, S., Lee, H., Lee, J. *et al*. (2021) 999 Causal Effects of Serum Levels of n-3 or n-6 Polyunsaturated Fatty Acids on Coronary Artery Disease: 1000 Mendelian Randomization Study. Nutrients, 13. 1001 79 Hemani, G., Bowden, J. and Davey Smith, G. (2018) Evaluating the potential role of 1002 pleiotropy in Mendelian randomization studies. Hum Mol Genet, 27, R195-R208. 1003 80 Baylin, A., Ruiz-Narvaez, E., Kraft, P. and Campos, H. (2007) alpha-Linolenic acid, Delta6-1004 desaturase gene polymorphism, and the risk of nonfatal myocardial infarction. Am J Clin Nutr, 85, 1005 554-560. 1006 81 Vaittinen, M., Walle, P., Kuosmanen, E., Mannisto, V., Kakela, P., Agren, J., Schwab, U. and 1007 Pihlajamaki, J. (2016) FADS2 genotype regulates delta-6 desaturase activity and inflammation in 1008 human adipose tissue. J Lipid Res, 57, 56-65. 1009 82 Marklund, M., Morris, A.P., Mahajan, A., Ingelsson, E., Lindgren, C.M., Lind, L. and Riserus, U. 1010 (2018) Genome-Wide Association Studies of Estimated Fatty Acid Desaturase Activity in Serum and 1011 Adipose Tissue in Elderly Individuals: Associations with Insulin Sensitivity. Nutrients, 10. 1012 83 Freemantle, E., Lalovic, A., Mechawar, N. and Turecki, G. (2012) Age and haplotype 1013 variations within FADS1 interact and associate with alterations in fatty acid composition in human 1014 male cortical brain tissue. PLoS One, 7, e42696. 1015 Wang, L., Athinarayanan, S., Jiang, G., Chalasani, N., Zhang, M. and Liu, W. (2015) Fatty acid 84 1016 desaturase 1 gene polymorphisms control human hepatic lipid composition. *Hepatology*, **61**, 119-1017 128. 1018 85 Gkatzionis, A. and Burgess, S. (2019) Contextualizing selection bias in Mendelian 1019 randomization: how bad is it likely to be? Int J Epidemiol, 48, 691-701. 1020 Imamura, F., Micha, R., Wu, J.H., de Oliveira Otto, M.C., Otite, F.O., Abioye, A.I. and 86 1021 Mozaffarian, D. (2016) Effects of Saturated Fat, Polyunsaturated Fat, Monounsaturated Fat, and 1022 Carbohydrate on Glucose-Insulin Homeostasis: A Systematic Review and Meta-analysis of 1023 Randomised Controlled Feeding Trials. PLoS Med, 13, e1002087.

1024 87 Koletzko, B., Reischl, E., Tanjung, C., Gonzalez-Casanova, I., Ramakrishnan, U., Meldrum, S., 1025 Simmer, K., Heinrich, J. and Demmelmair, H. (2019) FADS1 and FADS2 Polymorphisms Modulate 1026 Fatty Acid Metabolism and Dietary Impact on Health. Annu Rev Nutr, 39, 21-44. 1027 Mitchell, J.A. and Warner, T.D. (2006) COX isoforms in the cardiovascular system: 88 1028 understanding the activities of non-steroidal anti-inflammatory drugs. Nat Rev Drug Discov, 5, 75-86. 1029 89 Ntambi, J.M., Miyazaki, M., Stoehr, J.P., Lan, H., Kendziorski, C.M., Yandell, B.S., Song, Y., 1030 Cohen, P., Friedman, J.M. and Attie, A.D. (2002) Loss of stearoyl-CoA desaturase-1 function protects 1031 mice against adiposity. Proc Natl Acad Sci U S A, 99, 11482-11486. 1032 90 Cohen, P., Miyazaki, M., Socci, N.D., Hagge-Greenberg, A., Liedtke, W., Soukas, A.A., Sharma, 1033 R., Hudgins, L.C., Ntambi, J.M. and Friedman, J.M. (2002) Role for stearoyl-CoA desaturase-1 in 1034 leptin-mediated weight loss. Science, 297, 240-243. 1035 Brown, J.M., Chung, S., Sawyer, J.K., Degirolamo, C., Alger, H.M., Nguyen, T., Zhu, X., Duong, 91 1036 M.N., Wibley, A.L., Shah, R. et al. (2008) Inhibition of stearoyl-coenzyme A desaturase 1 dissociates 1037 insulin resistance and obesity from atherosclerosis. Circulation, **118**, 1467-1475. 1038 MacDonald, M.L., van Eck, M., Hildebrand, R.B., Wong, B.W., Bissada, N., Ruddle, P., 92 1039 Kontush, A., Hussein, H., Pouladi, M.A., Chapman, M.J. et al. (2009) Despite antiatherogenic 1040 metabolic characteristics, SCD1-deficient mice have increased inflammation and atherosclerosis. 1041 Arterioscler Thromb Vasc Biol, 29, 341-347. 1042 93 Jensen, P.N., Fretts, A.M., Hoofnagle, A.N., Sitlani, C.M., McKnight, B., King, I.B., Siscovick, 1043 D.S., Psaty, B.M., Heckbert, S.R., Mozaffarian, D. et al. (2020) Plasma Ceramides and Sphingomyelins 1044 in Relation to Atrial Fibrillation Risk: The Cardiovascular Health Study. J Am Heart Assoc, 9, e012853. 1045

40

1047 FIGURE TITLES AND LEGENDS

1048

Figure 1. Overview of desaturation and elongation reactions involved in the conversion of
MUFA from SFA and of longer-chain omega-3 and omega-6 PUFA from their shorter chain
precursors.

Red boxes highlight enzymes encoded by genes mapped to genetic variants strongly associated with circulating
fatty acids in genome-wide association studies: delta-5 desaturase (D5D), delta-6 desaturase (D6D), fatty acid
elongase 2 (ELOVL2), and stearoyl-CoA desaturase (SCD) encoded by *FADS1* (ENSG00000149485), *FADS2*(ENSG00000134824), *ELOVL2* (ENSG00000197977), *SCD* (ENSG00000099194), respectively.

1056 Saturated fatty acids (SFA): PA: palmitic acid; SA: stearic acid. Monounsaturated fatty acids (MUFA): POA: 1057 palmitoleic acid; OA: oleic acid. ω -6 polyunsaturated fatty acids (PUFA): LA: linoleic acid; GLA: γ -linolenic 1058 acid; EDA: eicosadienoic acid; DGLA: dihomo- γ -linolenic acid; AA: arachidonic acid; ADA: adrenic acid; 1059 TTA: tetracosatetraenoic acid; TPA: tetracosapentaenoic acid; DPA: docosapentaenoic acid. ω -3 1060 polyunsaturated fatty acids (PUFA): ALA: α -linolenic acid; SDA: stearidonic acid; ETE: eicosatrienoic acid; 1061 ETA: eicosatetraenoic acid; EPA: eicosapentaenoic acid; DPA: docosapentaenoic acid; TPA: 1062 tetracosapentaenoic acid; THA: tetracosahexaenoic acid; DPA: docosahexaenoic acid;

1063

Figure 2. Schematic representation of multiple putative mechanisms underlying the association of genetic variants with fatty acids biosynthesis and cardiovascular disease (CVD) risk.

1067 Figure 2A represents vertical pleiotropy, in which the effect of genetic instruments on CVD is mediated by fatty 1068 acids biosynthesis. Figures 2B to 2E represent alternative mechanisms that could bias Mendelian randomization 1069 findings: horizontal pleiotropy (2B), in which the genetic variant influences fatty acids biosynthesis and CVD 1070 via two different biological pathways, (2C) confounding by linkage disequilibrium (LD), in which the selected 1071 genetic variant is in LD with another genetic variant influencing CVD independently, (2D) confounding, in 1072 which different phenomena can introduce spurious association between genetic variant and CVD in samples of 1073 unrelated individuals, and (2D) selection bias, in which selection into the study creates a spurious association 1074 between genetic variant and CVD due to collider stratification bias. MVMR: multivariable Mendelian 1075 randomization.

1076

Figure 3. Mendelian randomization results for the risk of cardiovascular diseases related to
 increasing activity of enzymes coded by *FADS1/2* (D5D/D6D), *ELOVL2* (ELOVL2) and
 SCD (SCD) among individuals of European and East Asian ancestries.

1080 Results are expressed as odds ratio of cardiovascular diseases per standard unit increase in the marker of enzyme
1081 activity for *FADS1/2* (i.e. AA:DGLA ratio in Europeans and DGLA:LA ratio in East Asians), *ELOVL2* (i.e.
1082 DHA:DPA ratio in Europeans) and *SCD* (i.e. POA:PA ratio in Europeans) loci. For individuals of European
1083 ancestry, SNP-cardiovascular diseases association data were metanalysed across multiple genetic association
1084 consortia, UK Biobank and FinnGen. For individuals of East Asian ancestry, SNP-cardiovascular diseases

41

1085 association data were extracted from BioBank Japan. Full symbols indicate associations at P-value lower than 1086 the P-value threshold accounting for multiple testing (P < 0.006 for Europeans and P < 0.008 for East Asians). 1087 AA: arachidonic acid; DGLA: dihomo-γ-linolenic acid; DHA: docosahexaenoic acid; DPA: docosapentaenoic 1088 acid; LA: linoleic acid; PA: palmitic acid; POA: palmitoleic acid; SNP: single nucleotide polymorphism; 1089 FADS1/2: fatty acids desaturase 1/2; ELOVL2: elongase 2; SCD: stearoyl-CoA desaturase.

1090

1091 Figure 4. Mendelian randomization results for cardiovascular risk factors related to 1092 increasing activity of enzymes coded by FADS1/2 (D5D/D6D), ELOVL2 (ELOVL2) and

1093 SCD (SCD) among individuals of European and East Asian ancestries.

1094 Results are expressed as change in standard units or log odds ratio of cardiovascular disease risk factors per 1095 standard unit increase in the marker of enzyme activity for FADS1/2 (i.e. AA:DGLA ratio in Europeans and 1096 DGLA:LA ratio in East Asians), ELOVL2 (i.e. DHA:DPA ratio in Europeans) and SCD (i.e. POA:PA ratio in 1097 Europeans) loci. For individuals of European ancestry, data was extracted from multiple consortia of genetic 1098 association studies. For individuals of East Asian ancestry, data was extracted from BioBank Japan. Full 1099 symbols indicate associations at P-value lower than the P-value threshold accounting for multiple testing (P <1100

0.00625). Smoking is represent by pack years of smoking and number of cigarettes per day in European and 1101

East Asian ancestry individuals, respectively. FADS1/2: fatty acids desaturase 1/2; ELOVL2: elongase 2; SCD:

1102 stearoyl-CoA desaturase; LDL-cholesterol: low-density lipoprotein-cholesterol.

1103

1104 Figure 5. Phenome wide association scan of FADS1/2 (rs174546), ELOVL2 (rs3734398) and

1105 SCD (rs603424) genetic variants in European and East Asian ancestry individuals.

1106 Results are expressed as the Z-statistic for the variant-trait association for the allele increasing enzyme 1107 expression/activity. Red circles denote P-value $< 1.5 \times 10^{-6}$ in Europeans P-value $< 4.5 \times 10^{-4}$ in East Asians 1108 . FADS: fatty acids desaturase; ELOVL2: elongase 2; SCD: stearoyl-CoA desaturase.

1109

1110 Figure 6. Association of FADS1/2 (rs174546), ELOVL2 (rs3734398) and SCD (rs603424)

1111 genetic variants with expression of cis-genes across multiple tissues among Europeans.

1112 Results are expressed as z-statistics (effect estimate / standard error) for the SNP-gene expression association 1113 per allele increasing enzyme activity. Only cis-genes (i.e. SNP within 1Mb up- or down-stream of the gene's 1114 transcription start site) were included in the analysis. Genes are labelled in the plot if P-value < 5% FDR per 1115 tissue.

1116

```
1117
        Figure 7. Association of FADS1/2 (rs174546), ELOVL2 (rs3734398) and SCD (rs603424)
1118
        genetic variants with cardiovascular risk factors among unrelated individuals and within
1119
        siblings of European ancestry.
```

1120 Results are expressed as change in standard deviation (SD) units (or risk difference), and 95% confidence

1121 intervals (95% CI), of cardiovascular risk factors per allele increasing enzyme activity.

Figure 1





44



Figure 3



46

FADS1/2: Europeans

Figure 5





● NS ● Log2 FC ● P ● P & Log2 FC 20 15 Total choles Triglyceride ٩ Platelet count Total protein $-Log_{10}$ 10 Albumin/globulin ratio Alanine aminotra Herroglobin A1c Red blood tell coun 5 ì 0 -10 0 10 Ζ Total = 110 variables

FADS1/2: East Asians

ELOVL2: Europeans

● NS ● Log2 FC ● P & Log2 FC



SCD: Europeans

NS Log2 FC P & Log2 FC



Total = 33086 variables

Total = 31501 variables



